April 18, 2019
CMIC HOLDINGS Co., Ltd.
CMIC HOLDINGS Co., Ltd.(Head Office: Tokyo, Japan, Representative Director & CEO: Kazuo Nakamura）is pleased to announce that our new subsidiary company CMIC ASIA-PACIFIC (AUSTRALIA) PTY LTD（Head Office: Brisbane, Australia, Managing Director: Jane Chiu） has been established aiming to strengthen CRO business in Oceanian region.
CMIC Group regards the Oceanian region as a growing market for pharmaceuticals and medical devices. We have positioned the promotion of business in the region as one of our priority. The region is suitable for conducting clinical trials with a variety of races, such as Caucasian and Asian populations. In addition, Australia complies with the ICH/GCP and the data of the clinical trial can be utilized for applications in Europe and the United States. By establishing a local organization in Australia, we will respond to the rapidly growing needs of all our clients.
|(1) Firm name||CMIC ASIA-PACIFIC (AUSTRALIA) PTY LTD|
|(2) Head Office||Brisbane, Australia|
|(3) Main business||Pharmaceutical development support in Oceanian region|
|(4) Representative||Jane Chiu (Managing Director)|
【CMIC HOLDINGS Co., Ltd.】
CMIC Group started business in 1992 as the first CRO in Japan, and the company today provides comprehensive support services for the development, manufacturing, sales, and marketing of pharmaceutical products. Also, the company operates to respond to diversifying needs by managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan drugs. CMIC Group has developed a unique business model called Pharmaceutical Value Creator (PVC) based on its abundant accumulated experience and knowledge as a CRO pioneer. CMIC utilizes the PVC to create new value in the healthcare field.
For more information, visit CMIC Group’s website:https://www.cmicgroup.com/e/
CMIC HOLDINGS Co., Ltd. Corporate Communications Division, PR Group
TEL:03-6779-8200 / e-mail: email@example.com